About Provectus Biopharmaceuticals (OTCMKTS:PVCT)
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Trailing P/E Ratio-0.9775
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book7.82
Return on Equity-2,045.29%
Return on Assets-334.46%
Provectus Biopharmaceuticals (OTCMKTS:PVCT) Frequently Asked Questions
What is Provectus Biopharmaceuticals' stock symbol?
Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."
Who are some of Provectus Biopharmaceuticals' key competitors?
Some companies that are related to Provectus Biopharmaceuticals include Vernalis (VNLPY), Affimed (AFMD), Pain Therapeutics (PTIE), CytRx (CYTR), Acerus Pharmaceuti (TRLPF), OmniComm Systems (OMCM), Cleveland BioLabs (CBLI), BioSig Technologies (BSGM), Imprimis Pharmaceuticals (IMMY), Rewalk Robotics (RWLK), Oncobiologics (ONS), Tonix Pharmaceuticals (TNXP), RegeneRx Biopharmaceuticals (RGRX), Innovus Pharmaceuticals (INNV), Valeritas (VLRX), Soleno Therapeutics (SLNO), Soligenix (SNGX) and Cellectar Biosciences (CLRB).
Who are Provectus Biopharmaceuticals' key executives?
Provectus Biopharmaceuticals' management team includes the folowing people:
- Dominic Rodrigues, Chairman of the Board
- Timothy C. Scott Ph.D., President (Age 51)
- John R. Glass CPA, Interim Chief Financial Officer (Age 72)
- Eric A. Wachter Ph.D., Chief Technology Officer, Director (Age 52)
- Bruce Horowitz, Director
- Jan E Koe, Independent Director (Age 65)
How do I buy Provectus Biopharmaceuticals stock?
Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Provectus Biopharmaceuticals' stock price today?
One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.08.
How big of a company is Provectus Biopharmaceuticals?
Provectus Biopharmaceuticals has a market capitalization of $29.51 million. The company earns $-24,420,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. Provectus Biopharmaceuticals employs 2 workers across the globe.
How can I contact Provectus Biopharmaceuticals?
Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at 865-769-4011 or via email at [email protected]
MarketBeat Community Rating for Provectus Biopharmaceuticals (PVCT)MarketBeat's community ratings are surveys of what our community members think about Provectus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Provectus Biopharmaceuticals (OTCMKTS:PVCT) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Provectus Biopharmaceuticals (OTCMKTS:PVCT) Earnings History and Estimates Chart
Provectus Biopharmaceuticals (OTCMKTS PVCT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Provectus Biopharmaceuticals (OTCMKTS:PVCT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)
No dividend announcements for this company have been tracked by MarketBeat.com
Provectus Biopharmaceuticals (OTCMKTS PVCT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 0.03%
Provectus Biopharmaceuticals (OTCMKTS PVCT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/14/2017||John R Glass||Insider||Buy||200,000||$0.05||$10,000.00|| |
Provectus Biopharmaceuticals (OTCMKTS PVCT) News Headlines
Provectus Biopharmaceuticals (OTCMKTS:PVCT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Provectus Biopharmaceuticals (OTCMKTS PVCT) Stock Chart for Saturday, January, 20, 2018